Company intelligence / Profile preview

Calyxt

New Brighton, Minnesota, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Calyxt developed and commercialized the first U.S. seeds from "New Genetic Engineering" (gene edited soybeans) but faced commercial setbacks, notably low yields for farmers and exited that line; continues to develop crops with enhanced health/sustainability traits leveraging PlantSpring™ gene editing technology

Therapeutic areas: Other
Modalities: Gene editing (particularly "CRISPR-based therapy" for crops, but not classical medical therapeutics)
Industry: Non-Drug Biotech

Partnerships

Seed production companiesfood industry partners (ongoing licensing and tolling partnerships)academic collaborations (notably University of Minnesota, Iowa State University)

Beyond the preview

Go deeper on Calyxt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calyxt.

Explore the full profile